Cartogene Therapeutics

Cartogene Therapeutics is a Gurugram, India-based biotechnology startup founded in 2024, dedicated to making next-generation, personalized CAR-T cell therapies affordable and accessible in India and other low- and middle-income countries (LMICs). The company's lead program, CGT19, is a CD19-targeted CAR-T cell therapy in-licensed from US-based Vector BioMed, designed for the treatment of B-cell malignancies such as leukemia and lymphoma. Cartogene is establishing a state-of-the-art, GMP-compliant manufacturing facility in Manesar, Gurugram, with an annual capacity of nearly 700 therapies, utilizing a proprietary negative-selection technology to achieve a rapid 7-day manufacturing process and shorter vein-to-vein turnaround times. Looking forward, the company plans to expand its pipeline into multiple myeloma therapies to further address unmet needs in oncology.